Soaring to save lives Soaring to save lives Tackling health disparities through drone delivery of vaccines animals and livestock living in underserved communities
Distributing medicine globally with pharmaceutical logistics Distributing medicine globally with pharmaceutical logistics From Germany to Australia, here’s what it takes from operations and logistics to ensure patients get their medicine on time, every time.
New partnership to develop schizophrenia treatments New partnership to develop schizophrenia treatments Boehringer Ingelheim partners with Sosei Heptares to develop next generation schizophrenia treatments
Positive-CHMP-opinion-for-dabigatran-in-children Positive-CHMP-opinion-for-dabigatran-in-children Positive CHMP opinion received for use of dabigatran for the treatment and prevention of venous thromboembolic events in children
EC_approval_nintedanib_ILD_PF EC_approval_nintedanib_ILD_PF European Commission approves nintedanib for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
Boehringer Ingelheim Access to Healthcare Strategy last mile Boehringer Ingelheim Access to Healthcare Strategy last mile We aspire to be a leader in ensuring improved access by delivering more health to humans, animals and communities around the world.
In-Reach Africa initiatives successfully completed In-Reach Africa initiatives successfully completed We are proud to report the successful completion of Kuza Afya and Tiba Yako, two of our In-Reach Africa initiatives.
Boehringer Ingelheim collaborates with Circle Pharma Boehringer Ingelheim collaborates with Circle Pharma Boehringer Ingelheim collaborates with Circle Pharma to develop a first-in-class cyclin RxL inhibitor that can halt the growth of cancer cells
Agile working as a mindset Agile working as a mindset How does an agile mindset foster innovation? Read about collaboration, user-centricity and rapid learning cycles
TwistPak Mixing platform for swine vaccines TwistPak Mixing platform for swine vaccines TwistPak® allows for fresh mixing of Ingelvac CircoFLEX® and Ingelvac MycoFLEX® on farm in less than 5 seconds
Perceived burden of COPD is higher for younger patients Perceived burden of COPD is higher for younger patients New global survey reveals perceived burden of disease is greater in younger people living with COPD
Boehringer biopharmaceuticals China receives approval supply EU and US Boehringer biopharmaceuticals China receives approval supply EU and US Boehringer Ingelheim Biopharmaceuticals China receives approval for supply of EU and US markets
Boehringer Ingelheim Second Transforming Science Day Boehringer Ingelheim Second Transforming Science Day World-renowned top scientists and companies in R&D take the stage at Boehringer Ingelheim’s second Transforming Science Day
Transforming Science Day Europe Transforming Science Day Europe Oct. 2, 2023: Join us in London, or virtually, to learn more about our patient-centric approach to innovation, advancing pipeline and partnering approach.
Boehringer expands production site in Greece Boehringer expands production site in Greece Boehringer expands production site in Greece for new medicine
Boehringer Ingelheim announces appointments Boehringer Ingelheim announces appointments Boehringer Ingelheim announces appointments
License to develop new fibro-inflammatory disease treatments License to develop new fibro-inflammatory disease treatments License to develop new fibro-inflammatory disease treatments
SPEVIGO (spesolimab) wins 2023 Prix Galien USA Award SPEVIGO (spesolimab) wins 2023 Prix Galien USA Award SPEVIGO® (spesolimab) wins 2023 Prix Galien USA Best Orphan/Rare Diseases Solution Award
Lothar Halmer Lothar Halmer Dr. Lothar Halmer is Chief Quality Officer and leads the Global Quality Organization in providing quality products for our patients every day.
Our Biotech Story | Bioxcellence | Boehringer Ingelheim Our Biotech Story | Bioxcellence | Boehringer Ingelheim Discover our pioneering history & leadership in biotechnology, driving innovation in biopharmaceutical manufacturing & breakthrough therapies.
View from Both Sides of the Table View from Both Sides of the Table Scott DeWire, US Head of BD&L shares experiences that have taught him first-hand the foundations of successful partnerships
discontinuation-bi-1467335-diabetic-retinopathy discontinuation-bi-1467335-diabetic-retinopathy The discontinuation of the development of BI 1467335 in diabetic retinopathy has been announced
Boehringer Ingelheim Venture Fund invests precision antimicrobials Boehringer Ingelheim Venture Fund invests precision antimicrobials Boehringer Ingelheim Venture Fund invests in the development of precision antimicrobials